Fantastic.
Avexa Reports Superior Results in ATC Phase IIb Clinical Trial Update.
48 week data shows 90% of treated patients achieve undetectable viral loads
Key Highlights from the 48 week data.
• Increase in the percentage of patients with viral loads below detectable at week 48 compared to week
24
superior results than 24 wk data this is huge
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)